Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Share:
Related BMY
Benzinga's M&A Chatter for Thursday August 27, 2015
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
The Top 3 Medtech Buyout Rumors This Week (Investor's Business Daily)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA

 

Related Articles (BMY)

Get Benzinga's Newsletters